What were the main drivers of revenue growth in this quarter?

Revenue growth was primarily driven by an increase in the Pharmaceutical Distribution segment, which saw a 14% rise in operating revenue. This growth was supported by increased sales to both institutional (19% increase) and retail (10% increase) customers, reflecting broader industry trends like increased prescription drug usage and higher pharmaceutical prices.

Why did the gross profit margin decrease slightly despite revenue growth?

The slight decrease in the gross profit margin percentage from 4.87% to 4.69% is attributed to a shift in customer mix towards a higher proportion of large institutional, mail order, and chain accounts, which generally have lower gross margins, as well as ongoing competitive pricing pressures in the market. These factors were partially offset by improved buy-side margins.

How is the company managing its debt and liquidity?

Cencora (formerly AmerisourceBergen) maintains a robust liquidity position with significant availability under its revolving credit facilities and receivables securitization programs, totaling approximately $1.9 billion at December 31, 2002. The company issued $300 million in senior notes in November 2002 and used proceeds for debt repayment. While cash and cash equivalents decreased quarter-over-quarter due to working capital investments like increased inventory, the company expects future operating cash flows to be sufficient to meet its financial obligations.

What is the status of the company's merger integration and restructuring efforts?

The company continues to execute its integration plans, including the consolidation of its distribution network and elimination of duplicate administrative functions, aiming for approximately $150 million in annual synergies by fiscal year-end 2004. This involves closing facilities and opening new ones. Costs associated with these initiatives, such as employee severance and lease cancellations, are being recognized in accordance with the newly adopted SFAS No. 146, with specific charges noted for the quarter.

COR 10-Q Quarterly Report Q1 FY2003 — Revenue, Net Income, EPS

Summary

Cencora, Inc. (formerly AmerisourceBergen Corporation) reported a strong performance for the three months ended December 31, 2002. Total revenue increased by 15% year-over-year to $11.1 billion, driven primarily by the Pharmaceutical Distribution segment. Net income saw a significant jump of 37% to $92.7 million, leading to a 33% increase in diluted earnings per share to $0.84. This growth reflects improved operational efficiencies, cost management, and the positive impact of merger integration efforts. The company's balance sheet shows substantial growth in merchandise inventories and accounts receivable, indicating increased business activity. However, cash and cash equivalents decreased by $296.6 million compared to the prior quarter, largely due to increased inventory and operational investments. Despite the short-term decrease in cash, the company's liquidity remains robust with significant availability under its credit facilities and receivables securitization programs, supported by strong operating cash flows expected for the remainder of the fiscal year.

Key Highlights

1Total revenue increased by 15% to $11.1 billion for the quarter ended December 31, 2002.
2Net income rose significantly by 37% to $92.7 million.
3Diluted earnings per share (EPS) grew by 33% to $0.84.
4Gross profit margin decreased slightly to 4.69% from 4.87% year-over-year, attributed to changes in customer mix and competitive pricing.
5Operating expenses as a percentage of revenue decreased due to operational efficiencies and merger integration.
6The company continues its integration and facility consolidation plans, with costs expected to be recognized in accordance with SFAS No. 146.
7Liquidity remains strong, with substantial availability under revolving credit and receivables securitization facilities.

Cencora, Inc. Quarterly Report for Q1 Ended Dec 31, 2002

Summary

Key Highlights

Frequently Asked Questions